Figure 2.

BMD change trajectories of the switch to denosumab vs teriparatide in patients with prior bisphosphonate use. Teriparatide and denosumab demonstrated different changes in BMD; patients who switched to teriparatide showed a nonsignificant trend for greater increases in lumbar spine BMD than denosumab through the first 2 y. However, teriparatide users had BMD loss at the hip (both total hip and femoral neck) in the first year, with no overall change over 2 y. Time categorized into baseline (−24 to 3 mo), 12 mo (9 to 15 mo), and 24 mo (21 to 27 mo).